RxDoctor Payments Data

William Willis, MD

General Practice · Poteau, OKNPI 1205875846

Payments from drug & device makers

$1,012in general payments, 2019–2025

Across 63 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$256
  • GSK$126
  • Portola Pharmaceuticals, LLC$103
  • AstraZeneca$88
  • Pfizer$78
  • Exact Sciences$71
  • plus $290 from 13 others

What the payments were for

  • Food & beverage$1,012100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,012 in reported general payments places this provider in the 80th percentile of 1,086 general practice providers in Oklahoma.

See all general practice providers in Oklahoma

Medicare billing

Part B allowed, 2024
$312,396
Medicare patients
245
Services billed
5,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter101$73,319
OzempicSemaglutide46$58,265
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,545$49,178
EliquisApixaban54$40,796
Oxycodone Hcl627$16,845
Combivent RespimatIpratropium/Albuterol Sulfate35$16,477
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$12,700
LinzessLinaclotide12$11,105
Breo ElliptaFluticasone/Vilanterol26$10,186
MovantikNaloxegol Oxalate17$7,307
FetzimaLevomilnacipran Hcl14$6,602
SymbicortBudesonide/Formoterol Fumarate24$6,026
GemtesaVibegron12$5,806
Albuterol Sulfate HfaAlbuterol Sulfate215$5,327
MyrbetriqMirabegron11$5,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$126$96,204148 claims
Novo NordiskOzempic$15$58,26546 claims
PfizerEliquis$78$40,79654 claims
AbbVieLinzess, Fetzima, Synthroid$256$19,31356 claims
Boehringer IngelheimCombivent Respimat$18$16,47735 claims
AstraZenecaSymbicort$88$6,02624 claims
Sumitomo Pharma America, Inc.Gemtesa$48$5,80612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,086 general practice providers in Oklahoma.

Other general practice in Poteau

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →